Shizuoka, Japan

Hisashi Hosoe


Average Co-Inventor Count = 5.8

ph-index = 2

Forward Citations = 15(Granted Patents)


Company Filing History:


Years Active: 1992-1993

Loading Chart...
2 patents (USPTO):Explore Patents

Title: Hisashi Hosoe: Innovator in Pharmaceutical Chemistry

Introduction

Hisashi Hosoe is a prominent inventor based in Shizuoka, Japan. He has made significant contributions to the field of pharmaceutical chemistry, particularly in the development of novel compounds with therapeutic applications. With a total of 2 patents, his work focuses on anti-inflammatory agents and treatments for hepatic insufficiency.

Latest Patents

Hisashi Hosoe's latest patents include innovative compounds such as pyrazoloquinoline derivatives. These derivatives exhibit excellent anti-inflammatory activity and are designed to treat hepatic insufficiency. The formula for these compounds includes various substituents that enhance their pharmacological properties. Another notable patent involves anti-inflammatory 1,8-naphthyridin-2-one derivatives, which are characterized by their complex structures and potential therapeutic benefits.

Career Highlights

Throughout his career, Hisashi Hosoe has been associated with Kyowa Hakko Kogyo Co., Ltd., a leading company in the pharmaceutical industry. His work has contributed to advancements in drug development and has positioned him as a key figure in his field.

Collaborations

Hisashi Hosoe has collaborated with notable colleagues such as Fumio Suzuki and Kenji Ohmori. These partnerships have fostered innovation and have led to the successful development of new pharmaceutical compounds.

Conclusion

Hisashi Hosoe's contributions to pharmaceutical chemistry through his patents and collaborations highlight his role as an influential inventor. His work continues to impact the field positively, paving the way for future innovations in drug development.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…